Avenue Total Stockholder Equity vs Accounts Payable Analysis
| ATXI Stock | USD 3.63 0.07 1.97% |
Avenue Therapeutics financial indicator trend analysis is way more than just evaluating Avenue Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avenue Therapeutics is a good investment. Please check the relationship between Avenue Therapeutics Total Stockholder Equity and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.
Total Stockholder Equity vs Accounts Payable
Total Stockholder Equity vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avenue Therapeutics Total Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Avenue Therapeutics' Total Stockholder Equity and Accounts Payable is 0.42. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Avenue Therapeutics, assuming nothing else is changed. The correlation between historical values of Avenue Therapeutics' Total Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Avenue Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Stockholder Equity i.e., Avenue Therapeutics' Total Stockholder Equity and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.42 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Accounts Payable
An accounting item on the balance sheet that represents Avenue Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Avenue Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Avenue Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avenue Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.As of now, Avenue Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Avenue Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to 0.01, while Selling General Administrative is projected to decrease to under 3.3 M.
Avenue Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Avenue Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avenue Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 8.9M | 3.2M | 4.0M | 6.8M | 1.9M | 1.8M | |
| Other Current Liab | 1.7M | 714K | 147K | 2.6M | 795K | 986.7K | |
| Total Current Liabilities | 2.1M | 886K | 509K | 3.6M | 1.2M | 2.2M | |
| Total Stockholder Equity | 6.8M | 2.4M | 3.5M | 3.9M | 1.6M | 2.9M | |
| Net Tangible Assets | (631K) | 6.8M | 2.4M | 3.5M | 4.0M | 2.8M | |
| Net Debt | (8.7M) | (3.1M) | (3.8M) | (6.7M) | (1.8M) | (1.9M) | |
| Retained Earnings | (68.1M) | (73.3M) | (77.0M) | (80.6M) | (90.9M) | (86.4M) | |
| Accounts Payable | 368K | 172K | 362K | 970K | 401K | 381.0K | |
| Cash | 8.7M | 3.1M | 3.8M | 6.7M | 1.8M | 1.7M | |
| Cash And Short Term Investments | 8.7M | 3.1M | 3.8M | 6.7M | 1.8M | 1.7M | |
| Common Stock Shares Outstanding | 1.0M | 1.1M | 1.1M | 2.2M | 141.2K | 134.2K | |
| Liabilities And Stockholders Equity | 8.9M | 3.2M | 4.0M | 6.8M | 1.9M | 1.8M | |
| Non Current Liabilities Total | 0.0 | 3.6M | 368K | 172K | 362K | 949.0 | |
| Capital Surpluse | 38.9M | 41.6M | 74.9M | 75.6M | 87.0M | 91.3M | |
| Other Stockholder Equity | 74.9M | 75.6M | 80.4M | 84.5M | 92.5M | 59.9M | |
| Total Liab | 2.1M | 886K | 509K | 3.6M | 1.2M | 1.1M | |
| Total Current Assets | 8.9M | 3.2M | 4.0M | 6.8M | 1.9M | 1.8M | |
| Other Assets | 1.9M | 170K | 113K | 137.0 | 67K | 63.7K | |
| Other Current Assets | 170K | 113K | 107K | 137K | 67K | 129.6K | |
| Net Invested Capital | 6.8M | 2.4M | 3.5M | 3.9M | 1.6M | 1.5M | |
| Net Working Capital | 6.8M | 2.4M | 3.5M | 3.3M | 654K | 621.3K |
Currently Active Assets on Macroaxis
| SWKS | Skyworks Solutions | |
| AMGN | Amgen Inc | |
| SMAPX | Salient Mlp Energy | |
| MMM | 3M Company | |
| AMZN | Amazon Inc |
Additional Information and Resources on Investing in Avenue Stock
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share -1.1 K | Return On Assets (1.26) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.